Press Releases

Panbela Provides Business Update and Reports Q1 2022 Financial Results

Panbela to Host Virtual R&D Day

Panbela Schedules Conference Call on May 12 to Report 2022 Q1 Financial Results

Panbela Announces Poster Presentation at American Association for Cancer Research: The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer

Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28 at 12pm ET

Panbela to Participate in the 34th Annual Roth Conference

• Panbela management will participate in a fireside chat at the 34th Annual Roth Conference on March 14, 2022, at 11:30AM PT.
• The webcast will be available at: https://wsw.com/webcast/roth43/pbla/1805948

Panbela Schedules Conference Call on 3/24/22 to Report 2021 Fourth Quarter Financial Results

Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.

• Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needs
• Combined pipeline extends from pre-clinical to registration studies, with near-term clinical and regulatory milestones
• Acquired lead asset will begin a fully-funded registration trial anticipated to start by year-end